First Trust Advisors Reduces AbbVie Stake by Over 67%

Institutional investor sells over 1 million shares of pharmaceutical company

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

First Trust Advisors LP, an institutional investor, has reduced its stake in AbbVie Inc. (NYSE: ABBV) by 67.1% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm sold 1,007,670 shares of the pharmaceutical company's stock during the period.

Why it matters

This significant reduction in First Trust Advisors' AbbVie holdings could signal a shift in investor sentiment towards the company or the broader pharmaceutical industry. Institutional investors' trading activity is closely watched as it can provide insights into market trends and the perceived outlook for particular stocks.

The details

According to the 13F filing, First Trust Advisors LP now owns 494,551 shares of AbbVie's stock, valued at $114,508,000 at the end of the reporting period. The firm's previous holdings in AbbVie were 1,502,221 shares.

  • The transactions occurred in the third quarter of the reporting period.

The players

First Trust Advisors LP

An institutional investor and asset management firm.

AbbVie Inc.

A global, research-driven biopharmaceutical company that focuses on discovering, developing, and commercializing therapies for complex and often chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in First Trust Advisors' AbbVie holdings could signal a shift in investor sentiment towards the pharmaceutical company or the broader industry. Institutional investors' trading activity is closely watched as it can provide insights into market trends and the perceived outlook for particular stocks.